Iron as a therapeutic target for Parkinson's disease
Caroline Moreau, James A Duce, Olivier Rascol, Jean-Christophe Devedjian, Daniela Berg, David Dexter, Z Ioav Cabantchik, Ashley I Bush, David Devos
Movement Disorders | WILEY | Published : 2018
Awarded by European Commission Horizon PHC
This article refers to an academic study in progress with the French NS-Park network, which is funded by a grant from the European Commission Horizon 2020 PHC13 2014-2015 (633190): "Conservative iron chelation as a disease-modifying strategy in Parkinson's disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone (FAIR-PARK-II)"; protocol ID 2015_22; clinical trial: NCT02655315; http://fairpark2.eu. ApoPharma provided deferiprone and advice on the molecule.